Rifampicin in cutaneous leishmaniasis - a therapeutic trial in Saudi Arabia
DOI:
https://doi.org/10.66344/jpad.v16i1.838Keywords:
Cutaneous leishmaniasis, rifampicin, therapeutic trialAbstract
Background Osteoporosis is a common side-effect seen with long term steroid therapy. Patients at increased risk are over 50 years of age, postmenopausal, or have restricted mobility.
Objectives To assess the bone mineral density (BMD) in patients with pemphigus vulgaris (PV) on long term steroid therapy.
Patients and methods All patients with pemphigus vulgaris on oral/parenteral steroid therapy at the Department of Dermatology, Unit I, Mayo Hospital, Lahore were enrolled. Their BMD was measured at the heel with a quantitative ultrasound device. A control group comprising of 20 patients was also taken within the same time period that suffered from skin diseases other than pemphigus vulgaris and were not taking steroids in any form.
Results There were 25 patients, 14 males and 11 females, with an average age of 33.8 years (range 12-60 years). The average duration of PV was 24 months (6 months to 12 years). The steroids used by these patients included prednisolone, betamethasone and dexamethasone. The duration of intake ranged from 2 months to 36 months. The highest dose was 120 mg and lowest was 10 mg. The mean BMD score of the patients was 0.39244 g/cm2 and 0.45773 g/cm2 for the control group. The mean T-score of the patients was -2.31, score was -2.61in female patients and -2.08 in males. The score was -1.74 in the control group.
Conclusion All patients requiring long-term glucocorticoid therapy are candidates for osteoporosis prevention.
References
Onder M, Gurer MA. Leishmaniasis. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatment. London: Springer, 2000. p. 301-7.
Desjeux P. Cutaneous leishmaniasis; clinical aspects. In: Dowlati Y, Modabber F, eds. Clinics in Dermatology. New York: Elsevier, 1996. p. 417-23.
Peters W, Al-Zahrani MA. The leishmaniasis: a public health problem in Saudi Arabia. Saudi Med J 1987; 8: 333-43.
Rook A, Wilkinson DS, Ebling FTB et al. Textbook of Dermatology. Edinburgh: Blackwell Scientific Publication, 1986. p. 102l-*.
Gardener PJ, Shchory L. Chance ML. Species differentiation in the genus leishmania by morphometric studies with the electron microscope: Part I. Ann Trop Med Parasitol 1977; 71: 147– 56.
Sukkar F. Leishmaniasis in the Middle East. In: Chang KP, Brays RS, eds. Human Parasitic Disease, Vol. l. Amsterdam: Elsevier; 1985. p. 393-413.
Hepburn NC. Management of cutaneous leishmaniasis. Current Opinion Infectious Diseases 2001; 14: 151-4.
Alkhawaja AM, larbi E, Al-ghadin Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony; intramuscular vs intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
Bryceson ADM. Leishmaniasis. In: Wyngaarden JB, Smith Jr LH, eds. Cecil’s Textbook of Medicine. Edinburgh: Churchill Livingstone; 1980. p. 815-8.
Yardely V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrobial agents and chemotherapy 1997; 41; 752.
Osorio LE. Treatment of cutaneous leishmaniasis in Columbia with dapsone. Lancet 1998; 351: 1176.
Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
Kubba R, Al-Gindan Y, El-Hassan AM, Omer AHS. Ketoconazole in cutaneous leishmaniasis: results of a pilot study. Saudi Med J 1986; 7: 596-604.
Abdulwahab SA, Qasem AA, Nabeel NM, Amr IR. Cutaneous leishmaniasis in Kuwait, clinical experience with Itraconazole. Int J Dermatol 1991; 30: 237-9.
Hafez J, Al-Taqui M, Fowzy M et al. Cutaneous leishmaniasis in Kuwait: Part II. Therapeutic trial of Rifampicin and Pentostam. Arab J Med 1985; 4: 20-22.
Kochar DK, Aseri , Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000; 93: 733-738.
Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34; 702-9.
World Health Organization. Antimonials. Large scale failure in leishmaniasis "alarming." TDR News 1990:34.
Bahamdan K, Tallab TM, Nauri MM. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 1997; 36: 59.
Sharquie KE, Al-Talib KKA, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119:53-*
Aste N, Pau M, Biggio P. Intralesional treatment of cutaneous leishmaniasis with meglumine antimonite. Br J Dermatol 1998; 138: 370-*.
Soyuer U, Aktas E. Intralesional bleomycin therapy for leishmaniasis cutis. Arch Dermatol l988; 124: 1571.
Bryceson ADM, Bell SA. Occlusive paromomycin for cutaneous leishmaniasis. Lancet 1997; 349: 1477-*.
El-On J, Jacobos GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4: 76-81.
Bassiouny A, Meshad M, Talaat M et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; l07: 467-74.
Junaid AJN. Treatment of cutaneous leishmaniasis with infra-red heat. Int J Dermatol 1986; 25: 470-2.
Currie MA. Treatment of cutaneous leishmaniasis by curretage. Br Med J 1983; 287: 1105-6.
Long P. Cutaneous leishmaniasis treated with metronidazole. JAMA 1983; 223: 1378-9.
Pearson JK, Sawick S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975; 111: 1343-4.
Kandil E. Treatment of cutaneous leishmaniasis with trimethoprim-sulphamethoxazole. Dermatologica (Basel) 1973; 146: 303-30.
Selim MM, Kandil E. Rifampicin in the treatment of cutaneous leishmaniasis. J Kuwait Med Assoc 1972; 6: 159-*.
Pareek SS. Combination of sodium stibogluconate and rifampicin in cutaneous leishmaniasis. Int J Dermatol 1984; 23: 70-1.
Livshin R, El-On J, Weinrauch CL, Even-Paz Z. Therapeutic effect of rifampicin and isoniazid against L. major. Int J Dermatol 1983; 22: 61-*.
Khatri ML, Haider N. Cutaneous leishmaniasis in Yeman. Int J Dermatol 1999; 38: 587-90.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Huma Jaffar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
